Updated Oct 19, 2020 04:00 PM ET
After-Market: $8.36 -0.08 (-0.95%) 7:57 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
2-Buy of 5 2
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
F Value D Growth B Momentum F VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom.
Urovant Sciences Ltd
11-12 STREET JAMES SQUARE SUITE 1 3RD FLOOR
LONDON, X0 SW1Y 4LB
|Industry||Medical - Biomedical and Genetics|
|Fiscal Year End||March|
|Last Reported Quarter||9/30/2020|
|Next EPS Date||11/3/2020|
|Current Quarter EPS Consensus Estimate||-1.50|
|Current Year EPS Consensus Estimate||-6.73|
|Estimated Long-Term EPS Growth Rate||NA|
|Next EPS Report Date||11/3/2020|
Price and Volume Information
|52 Week High||15.98|
|52 Week Low||6.55|
|20 Day Moving Average||73,163.30|
|Target Price Consensus||23.33|
|Trailing 12 Months||NA|
|vs. Previous Year||-5.32%|
|vs. Previous Quarter||36.94%|
|vs. Previous Year||NA%|
|vs. Previous Quarter||NA%|
|Price / Sales||NA|